Alnylam New Data from Phase 3 in ATTR Amyloidosis with Cardiomyopathy

 − New Data Follow Recent U.S. FDA Approval of AMVUTTRA® (vutrisiran) as First RNAi Therapeutic to Reduce Cardiovascular Death, Cardiovascular Hospitalizations and Urgent Heart Failure Visits in Patients with ATTR-CM –

− Vutrisiran Favorably Impacted Echocardiographic Systolic and Diastolic Function –

− Vutrisiran Treatment Led to Maintenance or Improvement in Functional Capacity, Health Status, and Quality of Life, Compared to Placebo –

− Benefits of Vutrisiran Observed Across Baseline Heart Failure Severities, with Greatest Benefit in Patients with Early Disease –

− Findings Published in JACC −

https://finance.yahoo.com/news/alnylam-presents-data-helios-b-170000998.html